In a pilot study, EML4-ALK translocation was detected in plasma-derived EVs of patients with NSCLC, suggesting that EVs may serve as an additional tool to guide treatment with ALK inhibitors (Reclusa et al., 2019). This evidence concerns the gene ALK and non-small cell lung carcinoma.